when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVARTIS · news · pharmadog

← back to NOVARTIS

News mentioning NOVARTIS

367 stories

Sep 24, 26Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability databiospace

Sep 24, 26Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolutionstat

Sep 24, 26Growth mode: 3 biotechs that are staffing up after series B raisesbiospace

Sep 23, 26Roche, Ionis RNA drug scores in kidney disease studybiopharma dive

Sep 23, 26Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snagsfiercebiotech

Sep 23, 269 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europebiopharma dive

Sep 23, 26Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodbiospace

Sep 23, 26Novartis bets up to $900M for radioligand therapy from China’s BoomRaybiospace

Sep 23, 26Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSbiospace

Sep 23, 26The latest in the legal saga for youth gender-affirming care in the U.S.stat

Sep 23, 26Roche kidney drug's Phase 3 win sets up path to accelerated approvalendpoints

Sep 23, 26STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatmentsstat

Sep 23, 26Pharmas face off for manufacturing talent amidst reshoring effortsbiospace

Sep 23, 26Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease marketfiercebiotech

Sep 22, 26Amgen reports a Phase 3 win with Sjögren’s drug candidatebiopharma dive

Sep 22, 26Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand dealendpoints

Sep 22, 26Novartis secures new radioligand in $900M deal as competition strengthensfiercebiotech

Sep 22, 26Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin conditionfiercebiotech

Sep 22, 26Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 winfiercebiotech

Sep 21, 26Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsbiospace

Sep 21, 26Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapiesbiospace

Sep 21, 26Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&Abiospace

Sep 21, 26Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’biopharma dive

Sep 21, 26Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisitionfiercebiotech

Sep 21, 26Cue chalks up phase 2 hives win for Xolair challengerfiercebiotech

Sep 20, 26STAT+: Radiopharma companies merge after one receives surprise FDA rejectionstat

Sep 19, 26Another Novartis failure; Novo drops the ‘Nordisk’; and moreendpoints

Sep 18, 26This week in charts: GSK’s China deals, the $300M IPO club and selling the newsbiopharma dive

Sep 18, 26Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of movesendpoints

Sep 17, 26Lisata deal propels Marea’s drug pipeline to Wall Streetbiopharma dive

← prevpage 4 of 13next →